Top

Published in:

Open Access 01-12-2023 | Carcinoid Tumor | Letter to the Editor

Preliminary analysis of immune-related markers in thymic carcinoid

Authors: Jiaqi Zhang, Chao Guo, Lei Liu, Ke Zhao, Mengxin Zhou, Yeye Chen, Shanqing Li

Published in: Journal of Translational Medicine | Issue 1/2023

Abstract

The immune-related microenvironment of thymic carcinoid has rarely been reported. We analyzed the expression of PD-L1 and VISTA, and the distribution of CD4⁺ T cells, CD8⁺ T cells and CD68⁺ macrophages in the thymic carcinoid by immunohistochemical staining, and showed the correlation between these markers and clinical survival, indicating the potential therapeutic prospects.

WHO Classification of Tumours Editorial Board. Thoracic tumours (WHO classification of tumours series), vol. 5. 5th ed. Lyon: International Agency for Research on Cancer; 2021. p. 389. https://publications.iarc.fr/595.

Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010;236(1):219–42.CrossRefPubMedPubMedCentral

Liu M, Hu W, Zhang Y, et al. Clinical implications of immune checkpoint markers and immune infiltrates in patients with thymic neuroendocrine neoplasms. Front Oncol. 2022;12:917743.CrossRefPubMedPubMedCentral

Wu F, Jiang T, Chen G. Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non-small‐cell Lung cancer characterizes the features of response to PD‐1 blockade plus chemotherapy. Cancer Commun. 2022;42(12):1331–46.CrossRef

Loeser H, Kraemer M, Gebauer F. The expression of the immune checkpoint regulator VISTA correlates with improved overall survival in pT1/2 tumor stages in esophageal adenocarcinoma. Oncoimmunology. 2019;8(5):e1581546.CrossRefPubMedPubMedCentral

Title: Preliminary analysis of immune-related markers in thymic carcinoid
Authors: Jiaqi Zhang
Chao Guo
Lei Liu
Ke Zhao
Mengxin Zhou
Yeye Chen
Shanqing Li
Publication date: 01-12-2023
Publisher: BioMed Central
Keyword: Carcinoid Tumor
Published in: Journal of Translational Medicine / Issue 1/2023
Electronic ISSN: 1479-5876
DOI: https://doi.org/10.1186/s12967-023-04751-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2023

Latozinemab, a novel progranulin-elevating therapy for frontotemporal dementia

Dietary flavonoids intake contributes to delay biological aging process: analysis from NHANES dataset

Antileukemic effect of venetoclax and hypomethylating agents via caspase-3/GSDME-mediated pyroptosis

D-Mannose prevents bone loss under weightlessness

Deep dissection of stemness-related hierarchies in hepatocellular carcinoma

Cucurbitacin E reduces IL-1β-induced inflammation and cartilage degeneration by inhibiting the PI3K/Akt pathway in osteoarthritic chondrocytes

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials